Efficacy and Safety of TransCon PTH in Adults with Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial.

Clarke BL, Khan AA, Rubin MR, Schwarz P, Vokes T, Shoback DM, Gagnon C, Palermo A, Abbott LG, Hofbauer LC, Kohlmeier L, Cetani F, Pihl S, An X, Smith AR, Lai B, Ukena J, Sibley CT, Shu AD, Rejnmark L